Justices Mull Drug Disclosures In Matrixx Fraud Case

Law360, New York (January 10, 2011, 8:10 PM EST) -- The U.S. Supreme Court on Monday weighed the implications of companies disclosing rare or dubious claims of drug side effects to shareholders, battering attorneys for the plaintiffs and Matrixx Initiatives Inc. with hypotheticals involving psychics, Satan and “nutty-nutty” consumers.

The case, Matrixx Initiatives et al. v. Siracusano et al., raises the question of whether drug companies must reveal adverse event reports that do not show statistically significant evidence that a problem reported by patients is specifically caused by the use of the particular drug.

In the...
To view the full article, register now.